Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.
Leighann Forbes, PhD
Advertisement
Articles by Leighann Forbes, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD
2
New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression
3
Suicide Risk Assessment in Patients Denying Suicidal Intent
4
AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research
5